首页 News 正文

Panson signed a private merger agreement valuing the transaction at approximately $126 million

胡胡胡美丽_ss
278 0 0
On October 12, Panson issued an announcement announcing that it had officially signed a privatization merger agreement, corresponding to the valuation of the Pan-son transaction of about $126 million.

Under the agreement, Panson will merge with the parent company (New Genetron Holding Limited), and Panson will continue as a surviving entity and become a wholly-owned subsidiary of the parent company. The buyer group participating in the transaction includes CICC Concord Medical Fund, Wealth Strategy Holding Limited, Wuxi Guolian Group, CCB (Beijing) Investment Fund Management Co., LTD., Wuxi Huihong Yingkang Investment Partnership (Limited Partnership), etc.
According to the agreement, the purchase price per ordinary share is $0.272 and the purchase price per American Depositary Share (" ADS ", where each ADS represents five ordinary shares) is $1.36. According to the signed agreement, the transaction price represents a premium of approximately 15% to the last trading day before Panson announced that it had received the privatization offer; The offer represents a 21 per cent premium to the average closing price in the 30 trading days prior to the announcement of the take-private offer. As of October 11, 2023, the last trading day before the announcement, the premium is 42%.
The privatization transaction is expected to be completed in the first quarter of 2024, the announcement said.
Public information shows that Panson is a global cutting-edge precision cancer medicine company, providing early cancer screening, diagnosis and monitoring, drug research and development services covering the full cycle of cancer products and services, comprehensive coverage of China's top ten cancer types, and has "one step method", Mutation Capsule and other original research patented technology. In addition, Panson is the only precision medical enterprise that has entered the national major project of early screening of liver cancer, lung cancer, digestive tract cancer and other cancers of the Ministry of Science and Technology, and its lung cancer precision diagnosis and treatment project won the second prize of National Science and Technology Progress. (Li Gongsheng)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 【科技记者古尔曼:苹果计划于12月第一周发布iOS 18.2系统更新 带来更多人工智能功能】科技记者古尔曼透露,苹果计划于12月第一周发布iOS 18.2系统更新。iOS 18.2将为iPhone 15 Pro机型和所有iPhone 16机型带来更多 ...
    cristianna
    昨天 17:32
    支持
    反对
    回复
    收藏
  •   交易所监管文件显示,当地时间11月1日,亚马逊创始人杰夫·贝索斯拟出售约1635万股亚马逊股票,预计套现约30.5亿美元。今年7月,贝索斯已申请额外出售约2500万股亚马逊股票,按当时股价计算可套现约50亿美元。 ...
    blueskybb
    3 天前
    支持
    反对
    回复
    收藏
  •   近日,爱立信中国区总裁方迎在接受《经济参考报》记者采访时表示,5G技术在全球范围内得到了迅速发展,但面临商业潜力未能充分挖掘、网络运营难度较以往更高两大挑战。因此,运营商在继续5G网络部署的同时,应关 ...
    blueskybb
    昨天 15:05
    支持
    反对
    回复
    收藏
  •   近日,凯撒海湾目的地(山东)运营管理有限责任公司(简称“凯撒海湾”)与携程旅悦集团签署战略合作协议,双方将围绕“海上目的地运营”、“旅游产品与服务创新”、“研学旅行”、“日韩及海外旅游市场开拓”等 ...
    llyyy2008
    3 天前
    支持
    反对
    回复
    收藏
胡胡胡美丽_ss 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    34